Funding for this research was provided by:
Medizinische Hochschule Hannover (MHH)
Article History
Received: 1 June 2021
Accepted: 25 November 2021
First Online: 24 December 2021
Declarations
:
: The approval for the medical evaluation study was obtained from the independent research ethics committee of the University of Lübeck (Approval No.14 –249, dated 20 Nov 2014). As the participants had already consented to the use of their data for further analysis, no new ethics committee vote was needed for the present evaluation. Written informed consent was obtained from all study participants.
: Not applicable
: Martin Hochheim (MH) works part-time for the Generali Health Solutions GmbH (GHS), a company affiliated with the Generali Deutschland Krankenversicherung. Max Wunderlich (MW) is managing director of GHS, and Philipp Ramm (PR) is currently responsible for the back pain programme. All three declare that this research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Volker Amelung (VA) declares that he has no conflicts of interest to declare.